Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The augmentation of serotonin reuptake inhibitors (SRIs) with atypical antipsychotics for the management of treatment-resistant obsessive-compulsive disorder (OCD) is gaining increasing acceptance. Quetiapine is a novel antipsychotic which is well tolerated, and which may therefore be particularly useful in this context. Charts of all patients treated in our OCD clinic with the combination of an SRI and quetiapine were reviewed. Demographic details and clinical symptoms on the Yale-Brown Obsessive-Compulsive Scale and the Clinical Global Impressions Scale (CGI) were tabulated before and after augmentation. Eight OCD patients who had proven resistance to treatment with SRIs had received quetiapine augmentation. Four of these eight patients were responders (CGI of 1 or 2) within 4 weeks. In the treatment-responders, the medication was well tolerated. Although limited by the retrospective design and lack of controls, these data are consistent with the growing literature suggesting that approximately one-half of OCD patients resistant to treatment with SRIs may respond to augmentation with an atypical antipsychotic. Quetiapine, a relatively well tolerated agent, deserves further controlled study in this context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571 · cited 2×
“In addition, this does not appear to be limited to patients with comorbid tics (McDougle et al., 2000; Stein et al., 1997).”
Background
Cited by
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
(2004) · PubMed · Cited by 279
Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197
Heterogeneity of obsessive-compulsive disorder: A literature review
Lochner, C., & Stein, D. J. (2003) · Harvard Review of Psychiatry · doi:10.1080/10673220303949 · Cited by 143
Self-citationCarey, P. D., Vythilingum, B., Seedat, S., Muller, J. E., van Ameringen, M., & Stein, D. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-5 · Cited by 133
“These include support for risperidone [5-7], olanzapine [8-13], and more recently amisulpride [14] and quetiapine [15-18].”
Self-citation
Metadata
- Authors
- Mohr, N., Vythilingum, B., Emsley, R. A., & Stein, D. J.
- Venue
- International Clinical Psychopharmacology
- Published
- 2002-01
- Volume
- 17
- Issue
- 1
- Pages
- 37-40
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1971358252
- Cited by
- 68
- References
- 1
- FWCI
- 14.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. https://app.cochat.ai/papers/10.1097/00004850-200201000-00006
- The paper
- Mohr, N., Vythilingum, B., Emsley, R. A., & Stein, D. J. (2002). Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200201000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.